Pfizer +

Pfizer

Company

Ticker

PFE

LLY

JNJ

ABBV

Headquarter

New York City ,NY

Indianapolis ,IN

New Brunswick ,NJ

North Chicago ,IL

CEO

Albert Bourla

David A. Ricks

Joaquin Duato

Robert A. Michael CPA

Industry

Drug Manufacturers - General

Stock Price

Market Cap

$139.58 B

$705.16 B

$428.66 B

$374.63 B

Employees

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Employees

83.00 K
88.00 K
81.00 K

39.00 K
43.00 K
47.00 K

141.70 K
152.70 K
138.10 K

50.00 K
50.00 K
55.00 K

Y/Y

5.06%

6.02%

7.95%

11.43%

10.26%

9.3%

5.35%

7.76%

9.56%

10%

Income Statement

Revenue

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Revenue

$100.33 B
$59.55 B
$63.63 B

$28.54 B
$34.12 B
$45.04 B

$79.99 B
$85.16 B
$88.82 B

$58.05 B
$54.32 B
$56.33 B

Y/Y

23.43%

40.64%

6.84%

0.79%

19.56%

32%

1.59%

6.46%

4.3%

3.3%

6.44%

3.71%

Revenue by Products / Services

Revenue by Geography

Research and Development

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Research and Development

$11.43 B
$10.58 B
$10.74 B

$7.19 B
$9.31 B
$10.99 B

$14.14 B
$15.09 B
$17.23 B

$6.51 B
$7.68 B
$12.79 B

Y/Y

17.37%

7.42%

1.51%

3.75%

29.52%

18.01%

0.99%

6.72%

14.23%

19.09%

17.9%

66.66%

Operating Income

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Operating Income

$37.55 B
$5.29 B
$16.48 B

$8.65 B
$10.79 B
$17.50 B

$21.01 B
$23.41 B
$22.15 B

$18.12 B
$12.76 B
$9.14 B

Y/Y

80.58%

85.91%

211.47%

9.08%

24.66%

62.24%

0.33%

11.4%

5.38%

1.08%

29.59%

28.38%

Tax Rate (%)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Tax Rate (%)

10.00%
-105.00%
0.00%

8.00%
20.00%
16.00%

15.00%
12.00%
16.00%

12.00%
22.00%
-15.00%

Y/Y

25.72%

1199.06%

99.67%

11.48%

143.03%

17.76%

115.04%

25.32%

36.25%

9.2%

81.92%

169.63%

Net Income

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Net Income

$31.37 B
$2.13 B
$8.02 B

$6.24 B
$5.24 B
$10.59 B

$17.94 B
$35.15 B
$14.07 B

$11.84 B
$4.86 B
$4.28 B

Y/Y

41.62%

93.2%

276%

11.88%

16.08%

102.08%

14.07%

95.94%

59.99%

2.55%

58.91%

12.03%

Revenue Per Employee

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Revenue Per Employee

$1.21 M
$676.74 K
$785.52 K

$731.83 K
$793.58 K
$958.36 K

$555.68 K
$557.69 K
$643.16 K

$1.16 M
$1.09 M
$1.02 M

Y/Y

17.48%

44.02%

16.07%

9.55%

8.44%

20.76%

9.5%

0.36%

15.33%

3.3%

6.44%

5.72%

Net Income Per Employee

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Net Income Per Employee

$377.89 K
$24.24 K
$99.01 K

$160.12 K
$121.87 K
$225.32 K

$147.34 K
$230.21 K
$101.85 K

$236.72 K
$97.26 K
$77.78 K

Y/Y

34.8%

93.59%

308.49%

0.41%

23.89%

84.89%

34.68%

56.24%

55.76%

2.55%

58.91%

20.03%

Assets & Liabilities | Cash Flow

Total Assets

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Total Assets

$197.21 B
$226.50 B
$213.40 B

$49.49 B
$64.01 B
$78.71 B

$187.38 B
$167.56 B
$180.10 B

$138.81 B
$134.71 B
$135.16 B

Y/Y

8.67%

14.86%

5.79%

1.4%

29.33%

22.98%

2.94%

10.58%

7.49%

5.27%

2.95%

0.33%

Total Liabilities

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Total Liabilities

$101.29 B
$137.21 B
$124.90 B

$38.71 B
$53.14 B
$64.44 B

$110.57 B
$98.78 B
$108.61 B

$121.52 B
$124.31 B
$131.80 B

Y/Y

2.62%

35.47%

8.97%

2.36%

37.27%

21.26%

2.39%

10.66%

9.95%

7.3%

2.3%

6.02%

Capital Expenditures (Capex)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Capital Expenditures (Capex)

-$3.24 B
-$3.91 B
-$2.91 B

-$2.99 B
-$7.39 B
-$8.40 B

-$4.01 B
-$4.54 B
-$4.42 B

-$695.00 M
-$777.00 M
-$974.00 M

Y/Y

19.37%

20.74%

25.54%

50.89%

147.62%

13.68%

9.78%

13.32%

2.62%

11.69%

11.8%

25.35%

Profitability

Operating Income Margin (%)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Operating Income Margin (%)

37.43%
8.89%
25.91%

30.32%
31.61%
38.86%

26.27%
27.49%
24.94%

31.21%
23.49%
16.22%

Y/Y

46.33%

76.25%

191.45%

8.25%

4.25%

22.94%

1.24%

4.64%

9.28%

2.13%

24.74%

30.95%

Net Income Margin (%)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Net Income Margin (%)

31.26%
3.58%
12.60%

21.88%
15.36%
23.51%

22.43%
41.28%
15.84%

20.39%
8.95%
7.59%

Y/Y

14.72%

88.55%

251.96%

11.01%

29.8%

53.06%

15.42%

84.04%

61.63%

0.73%

56.11%

15.2%

EBITDA

2021	30793000000.00
2022	41031000000.00
2023	9557000000.00
2024	18127000000.00

2021	8042900000.00
2022	8660500000.00
2023	8567800000.00
2024	15227600000.00

2021	26751000000.00
2022	26605000000.00
2023	23320000000.00
2024	24781000000.00

2021	23933000000.00
2022	24174000000.00
2023	17172000000.00
2024	14910000000.00

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

EBITDA

$41.03 B
$9.56 B
$18.13 B

$8.66 B
$8.57 B
$15.23 B

$26.61 B
$23.32 B
$24.78 B

$24.17 B
$17.17 B
$14.91 B

Y/Y

33.25%

76.71%

89.67%

7.68%

1.07%

77.73%

0.55%

12.35%

6.27%

1.01%

28.97%

13.17%

Free Cash Flow (FCF)

2021	29869000000.00
2022	26031000000.00
2023	4793000000.00
2024	9835000000.00

2021	5387500000.00
2022	4600400000.00
2023	-3152000000.00
2024	414300000.00

2021	19758000000.00
2022	17185000000.00
2023	18248000000.00
2024	19842000000.00

2021	21990000000.00
2022	24248000000.00
2023	22062000000.00
2024	17832000000.00

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Free Cash Flow (FCF)

$26.03 B
$4.79 B
$9.84 B

$4.60 B
-$3.15 B
$414.30 M

$17.19 B
$18.25 B
$19.84 B

$24.25 B
$22.06 B
$17.83 B

Y/Y

12.85%

81.59%

105.2%

14.61%

168.52%

113.14%

13.02%

6.19%

8.74%

10.27%

9.02%

19.17%

Ratios

Return on Equity (ROE)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Return on Equity (ROE)

32.79%
2.40%
9.09%

58.64%
48.65%
74.62%

23.36%
51.11%
19.68%

68.60%
46.94%
128.66%

Y/Y

14.29%

92.68%

278.75%

5.66%

17.04%

53.38%

17.16%

118.79%

61.49%

8.42%

31.57%

174.09%

Return on Assets (ROA)

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Return on Assets (ROA)

15.90%
0.94%
3.76%

12.62%
8.19%
13.45%

9.57%
20.98%
7.81%

8.53%
3.61%
3.17%

Y/Y

30.33%

94.09%

300%

10.31%

35.1%

64.22%

16.56%

119.23%

62.77%

8.25%

57.68%

12.19%

Debt to Equity

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Debt to Equity

36.44%
79.59%
72.16%

152.48%
234.18%
237.06%

51.61%
42.65%
51.24%

372.04%
580.31%
2,040.33%

Y/Y

23.96%

118.41%

9.34%

18.91%

53.58%

1.23%

13.18%

17.36%

20.14%

26.1%

55.98%

251.59%

Valuation

Enterprise Value

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Enterprise value

$321.80 B
$230.45 B
$212.87 B

$361.79 B
$546.67 B
$725.64 B

$488.44 B
$404.57 B
$357.59 B

$341.20 B
$321.29 B
$376.67 B

Y/Y

12.03%

28.39%

7.63%

30.85%

51.1%

32.74%

3.87%

17.17%

11.61%

10.96%

5.83%

17.24%

Enterprise value to Revenue

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Enterprise value to Revenue

3.21
3.87
3.35

12.68
16.02
16.11

6.11
4.75
4.03

5.88
5.92
6.69

Y/Y

28.72%

20.65%

13.54%

29.83%

26.38%

0.56%

2.25%

22.2%

15.26%

7.41%

0.64%

13.04%

Enterprise value to EBITDA

Years

2022
2023
2024

2022
2023
2024

2022
2023
2024

2022
2023
2024

Enterprise value to EBITDA

7.84
24.11
11.74

41.77
63.81
47.65

18.36
17.35
14.43

14.11
18.71
25.26

Y/Y

33.98%

207.46%

51.3%

21.52%

52.74%

25.32%

4.44%

5.5%

16.82%

9.86%

32.56%

35.02%

Pfizer Competitors & Alternatives

Income Statement

Assets & Liabilities | Cash Flow

Profitability

Ratios

Valuation

Related company

Submit feedback to Bullfincher